Design, synthesis and evaluation of cytotoxic, antimicrobial, and anti-HIV-1 activities of new 1,2,3,4-tetrahydropyrimidine derivatives

Nima Razzaghi-Asl , Mahsa Kamrani-Moghadam, Behzad Farhangi, Rouhollah Vahabpour, Rezvan Zabihollahi, Saghi Sepehri


A series of new 1,2,3,4-tetrahydropyrimidine (THPM) derivatives were designed and synthesized within a one-pot three component Biginelli reaction. The structures of compounds were characterized by FT-IR, 1H-NMR, mass spectroscopy, and elemental analysis. All synthesized derivatives were screened for their cytotoxic, antimicrobial, and anti-HIV activities. Due to significant cytotoxic and antimicrobial effects of 1,2,3,4-THPM scaffold, in this study, cytotoxic and antimicrobial activities of synthesized derivatives were evaluated on two cell lines and four bacterial strains. Compounds 4e and 4k showed highest cytotoxic activity against HeLa and MCF-7 cell lines. In addition, 4c and 4d were most active against MCF-7 and HeLa cell lines, respectively. Among the compounds, 4e revealed high antimicrobial activity against four strains. According to the results, 4e possessing m-bromophenyl group at C-4 position of THPM exhibited the highest cytotoxic and antimicrobial effects. Also, all the newly synthesized compounds were evaluated for their anti-HIV-1 assay. Compounds 4l and 4a indicated remarkable anti-HIV-1 activity. It is concluded from cytotoxic, antimicrobial, and anti-HIV-1 activities that the 1,2,3,4-tertahydropyrimidines may serve as hit compounds for development of new anticancer small-molecules.


Anti-HIV; Antimicrobial; Biginelli; Neoplasm;1,2,3,4-Tetrahydropyrimidine.

Full Text:



American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.

Cherukupalli S, Chandrasekaran B, Krystof V, Aleti RR, Sayyad N, Merugu SR, et al. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Bioorg Chem. 2018;79:46-59.

Hosseinzadeh L, Aliabadi A, Rahnama M, Mir Mohammad Sadeghi H, Rahmani Khajouei M. Synthesis and cytotoxic evaluation of some new 3-(2-(2-phenylthiazol-4-yl) ethyl)-quinazolin-4(3H) one derivatives with potential anticancer effects. Res Pharm Sci. 2017;12(4):290-298.

Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A. Role of genomic alterations in HER2 positive breast carcinoma: focus on susceptibility and trastuzumab-therapy. Curr Cancer Drug Target. 2017;17(4):344-356.

Kumar B, Kumar R, Skvortsova I, Kumar V. Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials. Curr Cancer Drug Targets. 2017;17(4):357-375.

Kumar B, Sharma P, Gupta VP, Khullar M, Singh S, Dogra N, et al. Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies. Bioorg Chem. 2018;78:130-140.

Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284(19):1061-1065.

Kassab AE, Gedawy EM. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity. Eur J Med Chem. 2018;150:403-418.

Tenorio AR, Landay AL. HIV: so near and yet so far. Curr HIV/AIDS Rep. 2013;10(1):1-2.

Sepehri S, Saghaie L, Fassihi A. Anti‐HIV‐1 activity prediction of novel gp41 inhibitors using structure‐based virtual screening and molecular dynamics simulation. Mol Inform. 2017;36(3). DOI: 10.1002/minf.201600060.

Desai NC, Trivedi AR, Somani HC, Bhatt KA. Design, synthesis, and biological evaluation of 1,4- dihydropyridine derivatives as potent antitubercular agents. Chem Biol Drug Des. 2015;86(3):370-377.

Modarres Hakimi A, Lashgari N, Mahernia S, Mohammadi Ziarani G, Amanlou M. Facile one-pot four-component synthesis of 3,4-dihydro-2-pyridone derivatives: novel urease inhibitor scaffold. Res Pharm Sci. 2017;12(5):353-363.

Sośnicki JG, Struk L, Kurzawski M, Perużyńsk M, Maciejewsk G, Droździk M. Regioselective synthesis of novel 4,5-diaryl functionalized 3,4-dihydropyrimidine-2(1H)-thiones via a non-Biginelli-type approach and evaluation of their in vitro anticancer activity. Org Biomol Chem. 2014;12(21):3427-3440.

Chaudhari PK, Pandey A, Shah VH. Synthesis and biological studies of 1,2,3,4-tetrahydro pyrimidine derivatives. Orient J Chem. 2010;26(4):1377-1383.

Virsodia V, Manvar D, Pissurlenkar RRS, Coutinho E. Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxa. Eur J Med Chem. 2008;43(10):2103-2115.

Foroughifar N, Beromi SK, Pasdar H, Shahi M. Synthesis of some new tetrahydropyrimidine derivatives as possible antibacterial agent. Iran J Pharm Res. 2017;16(2):596-601.

Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SI, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;268(5441):971-974.

Debonis S, Skoufias DA, Indorato RL, Liger F, Marquet B, Laggner C, et al. Structure activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J Med Chem. 2008;51(5):1115-1125.

Soumyanarayanan U, Bhat VG, Kar SS, Mathew JA. Monastrol mimic Biginelli dihydropyrimidinone derivatives: synthesis, cytotoxicity screening against HepG2 and HeLa cell lines and molecular modeling study. Org Med Chem Lett. 2012;2:23-34.

Wright CM, Chovatiya RJ, Jameson NE, Turner DM, Zhu G, Werner S, et al. Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation. Bioorg Med Chem. 2008;16(6):3291-3301.

Sepehri S, Sanchez HP, Fassihi A. Hantzsch-Type Dihydropyridines and Biginelli-Type Tetrahydropyrimidines: A Review of their Chemotherapeutic Activities. J Pharm Pharm Sci. 2015;18:1-52.

Farrag AM, Harras MF, Ismail MMF. Design, synthesis and QSAR studies of novel 1,3,4-triarylpyrazoles as anti-breast cancer agents. J Pharm Appl Chem. 2017;3(1):63-74.

Raju BC, Rao RN, Suman P, Yogeeswari P, Sriram D, Shaik TB, et al. Synthesis, structure-activity relationship of novel substituted 4H-chromen-1,2,3,4-tetrahydropyrimidine-5-carboxylates as potential anti mycobacterial and anticancer agents. Bioorg Med Chem Lett. 2011;21(10):2855-2859.

Edayadulla N, Anand S, Shankar T. Synthesis and antibacterial evaluation of tetrahydropyrimidine-5-carboxamide. Asian J Chem. 2018;30(2):254-256.

Foroughifar N, Karimi Beromi S, Pasdar H, Shahi M. Synthesis of some new tetrahydropyrimidine derivatives as possible antibacterial agents. Iran J Pharm Res. 2017;16(2):596-601.

Sepehri S, Soleymani S, Zabihollahi R, Aghasadeghi MR, Sadat M, Saghaie L, et al. Design, synthesis, and anti‐HIV‐1 evaluation of a novel series of 1,2,3,4‐tetrahydropyrimidine‐5‐carboxylic acid derivatives. Chem Biodivers. 2018;15(4):e1700502.

Sepehri S, Gharagani S, Saghaie L, Aghasadeghi MR, Fassihi A. QSAR and docking studies of some 1,2,3,4-tetrahydropyrimidines: evaluation of gp41 as possible target for anti-HIV-1 activity. Med Chem Res. 2015;24(4):1707-1724.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65 (1-2):55-63.

Baker CN, Tenover FC. Evaluation of Alamar colorimetric broth microdilution susceptibility testing method for staphylococci and enterococci. J Clin Microbiol. 1996;34(11):2654-2659.

Olson WC, Maddon PJ. Resistance to HIV-1 entry inhibitors. Curr Drug Targets Infect Disord. 2003;3(4):283-294.

Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, et al. Evidence for differences in MT-2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rate among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(2):115-121.

Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986;59(2):284-291.

Campbell EM, Perez O, Melar M, Hope TJ. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology. 2007;360(2):286-293.

Sepehri S, Soleymani S, Zabihollahi R, Aghasadeghi MR, Sadat M, Saghaie L, et al. Synthesis, biological evaluation, and molecular docking studies of novel 4‐[4‐Arylpyridin‐1(4H)‐yl]benzoic acid derivatives as anti‐HIV‐1 agents. Chem Biodivers. 2017;14(12). DOI: 10.1002/cbdv.201700295.

Sachdeva H, Dwivedi D. Lithium-acetate-mediated biginelli one-pot multicomponent synthesis under solvent-free conditions and cytotoxic activity against the human lung cancer cell line A549 and breast cancer cell line MCF7. Sci World J. 2012;2012. DOI: 10.1100/2012/109432.

Elumalai K, Ashraf Ali M, Elumalai M, Eluri K, Srinivasan S. Novel isoniazid cyclocondensed 1,2,3,4-tetrahydropyrimidine derivatives for treating infectious disease: a synthesis and in vitro biological evaluation. J Acute Dis. 2013;2(4):316-321.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.